Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria

In paroxysmal nocturnal haemoglobinuria (PNH), chronic destruction of PNH red blood cells (RBCs) by complement leads to anaemia and other serious morbidities. Eculizumab inhibits terminal complement-mediated PNH RBC destruction by targeting C5. In the phase III, double-blind, placebo-controlled, TRI...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Schubert, Jörg, Hillmen, Peter, Röth, Alexander, Young, Neal S., Elebute, Modupe O., Szer, Jeffrey, Gianfaldoni, Giacomo, Socié, Gérard, Browne, Paul, Geller, Robert, Rother, Russell P., Muus, Petra
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7440627/
https://ncbi.nlm.nih.gov/pubmed/18503589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2008.07183.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados